In Simple Terms
People of the same age can show different patterns of aging inside their bodies. Scientists are studying proteins in the blood to see whether they can track those differences and show how the body responds to treatment. The approach could help researchers test ideas using samples from past studies, but it needs much more checking before doctors can rely on it.
Why Aging Does Not Follow One Clock
When two people of the same age seem to be in different states of health, the difference is not just about how they look. Changes inside their cells and organs may be happening at different rates, too. That is why the science of biological aging aims to measure what is happening in the body, rather than simply count the years since birth. One increasingly studied approach is to analyze proteins, which may reveal changes linked to inflammation, metabolism, and organ function.
These questions are the focus of a scientific webinar scheduled for Tuesday, December 1, 2026, at 08:00 Pacific Time, 11:00 Eastern Time, and 16:00 GMT. The speakers will discuss how sensitive, large-scale protein measurements might help track biological age and monitor the body’s response to treatments. Based on the information announced, the webinar will not present a ready-to-use clinical test. Instead, it will explore research findings, open questions, and possible ways to develop better tools.
Why Promising Ideas Need Evidence
Geroscience is built around a broad idea: if some biological processes associated with aging can be slowed, the onset of several chronic diseases might be delayed, rather than treating each disease in isolation. But that idea needs to be tested carefully. A change that looks beneficial in a laboratory or on a biological measure does not, by itself, show that people will live longer or enjoy better health.
That is where the evidence becomes a challenge. Clinical trials take time and resources, and tracking many outcomes over several years is difficult. At the same time, samples may remain in storage after trials have been completed, along with records of the interventions and participants’ health outcomes. If researchers can analyze those samples with modern tools, they may be able to screen ideas and identify interventions that merit larger studies. Such analysis, however, cannot replace the trials needed to establish whether a treatment truly helps.
Michael Corley, an associate professor of medicine at the University of California San Diego, is focused on the gap between the abundance of proposed ideas and the shortage of evidence that can be tested. In his scheduled presentation, he will discuss using stored samples from completed clinical trials to examine potential interventions. The approach could create new value from material already collected, provided the samples and data are suitable and the analysis allows fair comparisons among participants and outcomes.
Caution is essential. Finding a link between a particular protein and a health condition does not prove that the protein causes the condition, or that changing its level would improve it. Likewise, a biomarker that shifts after treatment may reflect the body’s response without providing enough evidence of a lasting health benefit. Researchers therefore need to combine molecular measurements with information from the clinical trial, then check whether the findings hold up in other groups.
What Protein Measurements Can Add
Proteins perform a wide range of jobs in the body. Some help transport substances or regulate the immune system; others are involved in inflammation or metabolism. Instead of measuring just one protein, proteomics technologies can examine a large collection of proteins in the same sample. Highly sensitive methods can detect proteins present at low levels, while multiplex measurements can reveal patterns of change rather than a single signal.
This broader view may be useful because aging is not one process. Immune pathways, metabolism, and tissue function may all change together, but not necessarily to the same degree. Protein patterns could help describe this complex picture or show whether an intervention is associated with shifts in several areas. Measuring more proteins also brings a challenge: the more indicators researchers examine, the more carefully they must control their analyses and repeat their findings to avoid mistaking chance results for real discoveries.
One intervention the webinar will discuss is a randomized trial of the drug semaglutide. Corley will present protein and epigenetic findings from the trial, focusing on changes in proteins related to heart health, metabolism, and inflammation during treatment and after the drug was stopped. The information announced does not include the number of participants, the size of the changes, or details about the treatment doses. It is therefore not possible to infer the magnitude or direction of the effects from the description alone.
Following what happens after people stop taking a drug matters scientifically because it can help distinguish a change that occurs during treatment from one that persists afterward. Looking at proteins alongside epigenetic markers may also provide different layers of information. That does not mean one method is always better than the other: each captures particular aspects of biology, and its sensitivity may depend on the research question, the time period, and the sample being studied.
A Protein-Based Clock Tested Across Three Groups
Xiao-Jun Ma, chief technology officer at Alamar Biosciences, will present a protein module identified using data from three research cohorts. According to the webinar description, the module tracks aspects of biological aging and was used to build a clock intended to estimate biological aging. This is a research tool based on a pattern of proteins—not a literal clock or a test that can determine a person’s actual age with absolute precision.
A measure becomes more valuable when researchers test how it relates to outcomes that matter to people, rather than simply showing that it describes laboratory data. Ma will discuss how the proposed clock was associated with mortality, cognitive abilities, and the burden of coexisting diseases. These associations can help researchers assess whether the measure captures differences that are meaningful for health. On their own, however, they do not prove that the clock can predict an individual’s fate or change it.
Another question is how the protein clock compares with clocks based on DNA methylation, chemical changes that help regulate gene activity. This comparison matters because different indicators may capture different aspects of biological age. If one measure detects a change that another misses, it could provide complementary information. But judging its accuracy and usefulness requires systematic comparisons and independent testing—not simply showing that its results are different.
The webinar will also consider what the data may reveal about when protein aging begins to accelerate. The question is not only whether the measure changes with age, but also when its rate of change picks up and whether that timing varies among people or groups. Answers could help researchers develop ideas about periods when an intervention might matter most. They would not, by themselves, identify the right time for treatment or prove that an intervention during a particular period would prevent disease.
From Individual Samples to a Shared Biobank
Whether a finding can be repeated in different groups is a basic test for any biomarker. A pattern seen in one group may reflect the participants’ characteristics, the way samples were collected, or the conditions under which they were analyzed. Identifying a protein module across three cohorts gives researchers a broader basis for assessment, but they will still need details about the cohorts and validation methods before they can judge how widely the measure applies.
This need connects to XPRIZE Healthspan, a global competition whose central biobank is expected to contain samples from 20 intervention trials. A well-organized collection of samples from multiple trials could allow researchers to test markers on a broader scale, compare responses to different interventions, and look for shared patterns. But bringing samples together does not guarantee sound conclusions. Those also depend on consistent measurement methods, well-documented information, and careful attention to the design of each trial.
When data are organized so that comparisons are possible, it becomes easier to assess whether a marker recurs across independent studies or appears only in a particular setting. Stored samples may also let researchers investigate effects that were not the focus of the original analysis, without having to collect all the material again. Practical limitations remain, however: differences among trials and participants, as well as missing data, can make comparisons complicated. Those limitations need to be made clear when the findings are interpreted.
What Makes a Biological Clock Useful?
Being able to measure biological age is not enough to make a tool useful. Its results need to be repeatable and reflect real change rather than measurement noise. The tool should also provide information beyond what is already available from chronological age or routine health tests. If the goal is to track a treatment’s effects, researchers need to know whether a change in the measure corresponds to an important health change—not just a shift in a laboratory number.
A clock should also be tested in diverse groups and with different interventions, and researchers need to define its limits. A tool may provide a useful estimate for research groups but be less accurate when applied to one person’s result. Protein markers can also be influenced by factors unrelated to aging. That makes it especially important to interpret the overall pattern in its clinical context, rather than treating a single protein as a final verdict.
Proteomics gives researchers a chance to observe the body’s responses in greater detail and opens the door to reexamining samples from earlier trials. At the same time, the abundance of molecular signals raises the bar for what needs to be demonstrated: findings must be validated, compared, and connected to clear health outcomes. In that sense, the most important achievement may not be creating a new aging clock in itself, but developing a reliable way to identify which biological changes deserve to be investigated as possible treatment targets.
The Bottom Line
The webinar scheduled for December 1, 2026, will examine how proteins might help researchers track biological aging and assess the body’s response to interventions. Topics include a randomized trial of semaglutide, a protein-based measure developed across three cohorts, and a planned biobank containing samples from 20 intervention trials. These approaches could help turn ideas into questions that can be tested, but they do not establish that a treatment can slow aging. The crucial next step is to validate the measures and link them to real health benefits, without mistaking a promising laboratory marker for a proven clinical outcome.